Table 3.
Concordance in external quality assessment (EQA; MIC and β-lactamase testing results only)
| Country | No. of susceptibility tests | % of isolates with MICs >2 doubling dilutions from the modal MIC (no.) |
|---|---|---|
| Austria | 210 | 1.4 (3) |
| Belgium | 500 | 0 |
| Cyprusa | 24 | 0 |
| Denmark | 420 | 0.5 (2) |
| France | 460 | 2.6 (12) |
| Greece | 291 | 0.3 (1) |
| Icelandb | 40 | 0 |
| Irelandc | 30 | 0 |
| Italy | 430 | 4.2 (18) |
| Malta | 230 | 1.3 (3) |
| Norway | 180 | 0.6 (1) |
| Portugal | 430 | 2.1 (9) |
| Slovenia | 730 | 0.6 (4) |
| Spain | 520 | 2.5 (13) |
| Sweden | 490 | 1.4 (7) |
| The Netherlands | 210 | 0 |
| United Kingdom | 510 | 3.1 (16) |
aLow number of isolates available and previously used disc diffusion method
bRecent Euro-GASP member and very low number of isolates available
cPreviously used disc diffusion method for EQA and therefore low number of EQA MIC results available